ALDX
Aldeyra Therapeutics, Inc.
Biotechnology · Healthcare · United States
0.56
close · 2026-10-30
value
7
cheaper than peers7
quality
84
stronger fundamentals84
ranked against
Biotechnology (pre-revenue)
value
quality
109 peerswide variation
Value inputs
| measure | company | vs peers |
| price to book | 0.89× | 84 |
| earnings yield, 2 years ago | -114.2% | 31 |
| earnings yield, 3 years ago | -189.2% | 23 |
| earnings yield, latest year | -99.9% | 20 |
| earnings yield, 1 year ago | -167.8% | 13 |
| cash flow yield, 2 years ago | -89.7% | 13 |
| cash flow yield, 1 year ago | -127.8% | 11 |
| cash flow yield, latest year | -98.7% | 11 |
| cash flow yield, 3 years ago | -167.6% | 5 |
9 of 12 measures available
Quality inputs
| measure | company | vs peers |
| debt to equity | 0.4% | 86 |
| return on equity | -49.5% | 66 |
| operating margin | 0.0% | 50 |
3 of 4 measures available
Facts
| market cap | $34M |
| free cash flow | -$13.9M |
| employees | 8 |
| first trade | 2014-05-02 |
| next earnings | not reported |
| fundamentals updated | 2026-08-13 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 | 2021 |
| diluted eps | -0.56 | -0.94 | -0.64 | -1.06 | not reported |
| free cash flow | -$33.3M | -$43.2M | -$30.3M | -$56.7M | not reported |
| net income | -$33.8M | -$55.9M | -$37.5M | -$62.0M | not reported |
| revenue | $0 | $0 | $0 | $0 | not reported |
| unusual items | not reported | not reported | not reported | not reported | $0 |